Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
You may also like Product Description PT-141 Peptide | Buy PT-141 UK | Research Use Only PT-141 also known as Bremelanotide and Vyleesi (FDA-approved pharmaceutical formulation) is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, MW 1,025.2 Da) originally derived as an active metabolite of Melanotan II and engineered as a non-selective melanocortin receptor agonist with highest affinity for MC4R, acting centrally in the medial preoptic area and paraventricular nucleus of the hypothalamus to modulate dopaminergic, noradrenergic, and serotoninergic neurotransmission governing sexual desire and arousal making it the only CNS-acting melanocortin system research tool with a full Phase II and Phase III clinical evidence base, FDA approval (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and a pharmacological profile mechanistically distinct from PDE5 inhibitors operating upstream on the neural circuitry of desire rather than downstream on vascular nitric oxide pathways
Barry Conrad Yeah, fair enough
In 2019 a multinational collaborative study of data collected in 204 countries and territories between 2000 and 2019 indicated that obesity contributed approximately 5 million deaths from major non-communicable diseases
Protein expression was detected by SuperSignal West Pico Chemiluminescent substrate (Thermo, Waltham, MA, USA) and Fujifilm LAS-3000 (Fujifilm, Tokyo, Japan)
,aspect=fit)
